Abstract: Disclosed herein are a composition and unit dosage form for the treatment of hepatitis C virus (HCV) infection comprising GS-7977 and at least one pharmaceutically acceptable excipient, as well as methods for making said composition and unit dosage form. Also disclosed herein is a method of treating a subject, preferably a human, infected with hepatitis C virus, said method comprising administering to the subject for a time period an effective amount of GS-7977 and an effective amount of ribavirin. In one aspect, the method comprises administering to the subject an interferon-free treatment regimen comprising an effective amount of GS-7977 and an effective amount of ribavirin. In a particular aspect, the method is sufficient to produce an undetectable amount of HCV RNA in the subject for at least 12 weeks after the end of the time period.

Abstract: The present invention relates to a nail varnish including at least one effect pigment and at least one micronized wax, and to a process for producing it. Furthermore, the invention relates to the use of at least one micronized wax in a nail varnish and to an article provided with the nail varnish. Moreover, the invention relates to a mixture of at least one pigment and at least one micronized wax.

Abstract: The invention is an antimicrobial photo-stable coating composition that deters photo-induced discoloration, does not stain tissue and can be applied to the surface of a variety of medical materials. The composition comprises in an aspect silver-PCA complex and dye.

Abstract: The embodiments provide a carbon nanocapsule conjugated with at least one of the anticoagulants on the surface and an antithrombotic drug containing the anticoagulant-conjugated carbon nanocapsule as an active ingredient. The anticoagulant-conjugated carbon nanocapsule has less cytotoxicity and good biocompatibility. A method for preparing the anticoagulant-conjugated carbon nanocapsule is also provided.

Abstract: The present invention relates to stable substantially non-aqueous, non-alcoholic, non-silicone, foamable carrier compositions comprising petrolatum or mixtures thereof, at least one foam agent, at least one propellant, and with and without the addition of an active agent. The formulations may contain a solvent substantially miscible therein. The present invention further provides a method of treating, alleviating or preventing a disorder of mammalian subject in need thereof, comprising administering the above-mentioned compositions to an afflicted target site of said mammalian subject.

Abstract: A medicinal carrier is provided. The medicinal carrier comprises a first component, which is a biocompatible polymer with an amino group (—NH2); a saccharide; and a second component which is a biocompatible material. The saccharide grafts to the first component via the amino group (—NH2) of the first component, and the first component bonds to the second component via an ionic bond. The medicinal carrier can protect the medicine from gastric acid and swell or decompose to release the medicine under a specific pH condition, thus, showing a good applicability.

Abstract: Provided are methods of treating obesity and effecting desired weight loss or preventing undesired weight gain by administration of a preferential muscarinic acetylcholine receptor M1 antagonist, optionally with at least one antidepressant other than a selective muscarinic acetylcholine receptor M1 antagonist. The preferential muscarinic acetylcholine receptor M1 antagonist, optionally can be administered with an anti-obesity agent, for example, an anorexiant. The invention also provides for pharmaceutical compositions and kits for administration of at least one selective muscarinic acetylcholine receptor M1 antagonist in combination with at least one antidepressant other than a selective muscarinic acetylcholine receptor M1 antagonist.

Abstract: The present disclosure relates to lipid compounds of the general formula (I): R1-O—C(R2)(R3)-X??(I) wherein R1 is a C10-C22 alkyl group, a C10-C22 alkenyl group having 1-6 double bonds, or a C10-C22 alkynyl group having 1-6 triple bonds; R2 and R3 are the same or different and may be chosen from different substituents; and X is a carboxylic acid or a derivative thereof, such as a carboxylic ester, a carboxylic anhydride, a phospholipid, triglyceride, or a carboxamide; or a pharmaceutically acceptable salt, solvate, solvate of such salt or a prodrug thereof. The present disclosure also relates to pharmaceutical compositions and lipid compositions comprising at least one compound according to the present disclosure, and to such compounds for use as medicaments or for use in therapy, in particular for the treatment of diseases related to the cardiovascular, metabolic, and inflammatory disease area.

Abstract: The inventions relates to a liquid pharmaceutical form containing an active ingredient alkylphosphocholines and a co-solvent system. The co-solvent system is mixture from hexylene glycol, propylene glycol, diethylene glycol monoethyl ether and water. The pharmaceutical form having a pH value in the range of 4 to 6, which if it is necessary can be achieved by adding a pH adjuster. The composition has a good storage stability and it is suitable for local application on the different organs of the body. The inventions relates also to a method for producing the same pharmaceutical form.

Abstract: One embodiment described herein is related to methods and compositions, such as nutraceutical formulations and dietary supplements, comprising C16:1n7-palmitoleate or derivatives thereof. The methods and compositions comprising C16:1n7-palmitoleate, or derivatives thereof, safely and effectively prevent or mitigate manifestations of cardiovascular disease, including coronary artery disease and the accumulation of cholesterol or lipid deposits in the blood vessels of a subject.

Abstract: A method for forming chocolate having cholecalciferol is provided. The method includes mixing cholecalciferol into an oil to produce a cholecalciferol-oil mixture. The temperature of a chocolate base is raised to a melting point, and the cholecalciferol-oil mixture is blended into the chocolate base to form a cholecalciferol-chocolate.

Abstract: A personal care composition is provided with a silicone compound and being aesthetically modified for improved skinfeel with a polyhydroxy quaternary ammonium salt of structure (I): wherein X? is selected from the group consisting of chloride, bromide, hydroxyl, sulphate, phosphate, methosulphate, carboxyl, citrate and tartrate; and (ii) from about 0.05 to about 50% of silicone by weight of the composition.

Abstract: Compositions, and methods of using such compositions, useful for injection into the posterior segments of human or animal eyes are provided. Such compositions include corticosteroid component-containing particles present in a therapeutically effective amount, a viscosity inducing component, and an aqueous carrier component. The compositions have viscosities of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity is in the range of from about 140,000 cps to about 300,000 cps. The compositions advantageously suspend the particles for prolonged periods of time.

Abstract: The production of starch containing products such as rice for use in a low glycemic diet as a carbohydrate substitute in diet preparations is disclosed. The preparation may be readily adjusted in form and taste with respect to aroma, texture, consistency, and flavor for utilization in a number of food preparation techniques including baking and frying. The method provides digestible starches from native and commercial starches by controlled heating and/or enzymatic processing and filtration of carbohydrates.